We are pleased to inform you of the survival results from the oncology “celecoxib comparisons” have now been published in The Journal of Clinical Oncology. Results from two of the comparisons of the STAMPEDE trial, adding the drug celecoxib (with or without zoledronic acid) to long-term hormone therapy for men with prostate cancer, were published yesterday in the Journal of Clinical Oncology. Overall, the results show no benefit in survival of adding either celecoxib alone, or celecoxib plus zoledronic acid, to long-term hormone therapy, but there are results of significant interest in the sub-group analyses. The results, looking at the entire group of men in the study, come as no surprise, since in 2012, a planned analysis of the trial showed that adding celecoxib, to hormone therapy did not add enough benefit to justify continuing to recruit more patients to these comparisons. The researchers continued to follow-up these men to monitor the long-term effects. These results (with an ...
MRC Clinical Trials Unit at UCL
90 High Holborn